Horizon cell line sequence released in bid to up bioproduction efficiency

By Dan Stanton contact

- Last updated on GMT

Image: iStock/kasto80
Image: iStock/kasto80

Related tags: Cell line, Gene, Cell culture

Horizon Discovery will allow researchers to modify a genome sequence based on its knock-out CHO K1 cell line in a bid to drive innovation in bioproduction.

Horizon is releasing the sequence as a reference tool for researchers to both screen for genes associated with desired phenotypes and to drive innovation in bioproduction in what the firm said was a rare move by a gene-editing company.

“Releasing the sequence will enable bioproduction researchers both in academia and industry to more easily modify their CHO cells through genome engineering, for example to increase product quality or yield,”​ Jamie Freeman, product manager at the UK-based translational genomics firm told Biopharma-Reporter.

“It is not common to be permitted to modify manufacturing ready cell lines in this manner. Therefore, by releasing the sequence we hope to drive innovation in the field, as well as increase uptake of our cell line.”

He added Horizon’s GS Knockout CHO cell line is widely accessible, with flexible licensing terms, “so we believe that it is logical to use our cells for these experiments, as the released sequence is the most accurate available.”

The project will also help Horizon further enhance the cell line using genome editing approaches, Freeman said. “We will use it to research and identify targets leading to future iterations of the cell line that will be released for commercial manufacturing with improved attributes for bioproduction.”

The sequence was done in collaboration with the Wellcome Trust Sanger Institute, and will be made available publicly via the Ensembl website at EMBL-EBI.

Related news

Show more

Related products

show more

Cultivation of 3D Cell Aggregates in Perfusion

Cultivation of 3D Cell Aggregates in Perfusion

Eppendorf for Bioprocess – Solutions that grow with you | 21-May-2018 | Application Note

3D cell aggregates are of great interest for applications like disease modeling and manufacturing of stem cell-based products. Read more about the cultivation...

High-Density Vero Cell Perfusion Culture

High-Density Vero Cell Perfusion Culture

Eppendorf for Bioprocess – Solutions that grow with you | 01-May-2018 | Application Note

Viral diseases like rabies, rotavirus and influenza are causing many deaths worldwide, resulting in a strong demand for more productive manufacturing techniques...

Nifty Biosimilar

Nifty Biosimilar

UGA Biopharma | 13-Mar-2018 | Research Study

Aflibercept (Zaltrap®) is a recombinant fusion protein with complex post-translational modifications. Therefore deep understanding of biosimilar development...

Featured eBook: Complex Protein Production

Featured eBook: Complex Protein Production

Catalent Pharma Solutions | 06-Mar-2018 | Technical / White Paper

Download the eBook written by Catalent experts to learn about innovative products and techniques for scale-up of complex biologics, get optimal cell culture...

Related suppliers